Verisante Technology (VRS:TSXV) was among the most liquid healthcare-related stocks on the TSX Venture Monday.


Verisante Technology’s shares rebound

Verisante Technology was up more than 50% at one point Monday on more than 600,000 shares traded. Some investors may remember Verisante from a few years ago when it dominated liquidity on the TSX Venture.

Verisante’s multispectral imaging (MSI) system was designed to revolutionize how doctors search for various forms of skin cancer. The technology is a form of imaging that captures data at different frequencies across the electromagnetic spectrum. These frequencies can include wavelengths not visible to the human eye, according to the company.

The company received huge media attention for its claims in 2011 as interest around future prototypes swelled. But, like the majority of small-cap stocks, in any sector, reality told a different story as the time and money needed to produce results and work through the regulatory approval process set in.

The above video was posted on YouTube on June 14th, 2011. Verisante’s shares were enroute to their all-time high and traded between $0.71 and $0.77 per share that day. A far cry, from Verisante’s high of $0.08which it hit today.

Verisante Technology was one of the most liquid stocks on the exchange in 2011 when it began its rally to above $1 per share.


Verisante Technology – 10 Year Chart


On November 12th, Verisante put out its first press release since early July when it announced a breakthrough in the fight against oral and skin cancer with a second phase prototype for the Company’s Intelligent Multispectral Imaging Camera.

The news went largely unnoticed as it was not distributed on the main outlets, including for example. Volume in Verisante’s stock was minimal last week, but exploded this morning.

The company chose not to release a typical press release, stating that:

“Press releases are short by nature and therefore detailed information is required to be left out. In response to the range of recent queries brought forward, Verisante is issuing a newsletter to clarify the scope of this new product and outline the positive effect it could have on the Company’s future growth.”

Click here to read the entire release.


In our latest EBook we reveal 50 leaders who took small-cap stocks to stunning multimillion and, in some cases, billion dollar buyouts. The companies these leaders run today are also described in this one of a kind rolodex of some of the top entrepreneurs and business minds, operating in North America’s small cap public markets.

Click the below image to get your free copy today.


Verisante’s MSI Camera

The secret sauce behind Verisante’s MSI Camera is that it has the potential to detect cancers that other technologies might miss. The company explains its camera in detail:

“Verisante has licensed the exclusive worldwide rights to a rapid MSI imaging system. The camera takes images of 18 different narrow band wavelengths of light in one third of a second to capture high definition multispectral images. From these multispectral images, unique information can be extracted about tissue oxygenation ratios, hemoglobin levels, melanin levels, scatter size, and other parameters which make the device useful to assist in oral and skin cancer detection applications.”

Click here to read the entire press release.

In a Canadian small-cap market that has seen better days, the Venture hovered near 525 this morning, patience is not something most retail investors have in abundance.

Verisante also reported its ‘next steps’ over the coming 12-24 month period. The completion of a laboratory for testing its skin cancer prototype and the building of 5 additional units to place in the field to gather data for its skin cancer device were at the top.

Also on the list for the company, was to begin applications for regulatory approvals. Clearly, this technology is still quite some time away from being commercialized.

In regards to revenue and the company’s potential impact in the space, it reports:

“The existence of a billing code for using the MSI Camera for oral cancer exams means the average dentist can add an estimated $20,000 or more to their annual revenue. This has driven sales of the above mentioned competing devices which have sold an estimated 30,000 units combined. It is Verisante’s goal to dominate this market with what the Company strongly believes is vastly superior technology.”

Whether or not Verisante Technology can gain regulatory approval for its MSI Camera and “dominate this market” are still unknowns. The company most recently closed a non-brokered private placement of 3,888,889 common shares at a price of $0.09 per share for gross proceeds of $350,000 almost one year ago on December 31st 2014. Dilution has to be a point of focus and concern for current shareholders as the company works to maintain its development schedule. However, with its potential market only growing and skin cancer rates on the rise in most countries, some investors have clearly not forgotten about this speculative healthcare-related stock.



This article represents solely the opinions of Alexander Smith. Alexander Smith is not an investment advisor and any reference to specific securities in the list referred to in the article does not constitute a recommendation thereof. Readers are encouraged to consult their investment advisors prior to making any investment decisions. The information in this article is of an impersonal nature and should not be construed as individualized advice or investment recommendations.

This is not an invitation to purchase any securities mentioned in this report. Pinnacle Digest does not endorse or recommend any of the referenced securities. At the time of publication and distribution of this report (11:30AM PST on November 16, 2015) neither, its employees or consultants owned shares in any of the mentioned companies in this report. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article. This report may contain technical or other inaccuracies, omissions, or typographical errors, for which and its parent company assumes no responsibility. We do not guarantee that any of the companies mentioned in this report or on will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect.

All statements in this report, other than statements of historical fact, should be considered forward-looking statements. These statements relate to future events or future performance. Much of this report is comprised of statements of projection. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. and its employees are not a registered broker-dealer or financial advisors. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Nothing in this article should be construed as a solicitation to buy or sell any securities. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article.